Phaseline

Companies › Sardocor

Sardocor: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 1; Cardiovascular; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SRD-001
AAV1-mediated SERCA2a gene therapy for SERCA2a enzyme replacement
ATP2A2Phase 1DMD-Associated Dilated Cardiomyopathy; Congestive Heart FailureOct 2027
AAV1/SERCA2a
Adeno-associated virus serotype 1 (AAV1) delivering SERCA2a gene to enhance cardiac calciu
ATP2A2Phase 1Heart Failure, DiastolicAug 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06224660SRD-001Phase 1DMD-Associated Dilated CardiomyopathyCardiovascularOct 2027
NCT04703842SRD-001Phase 1Congestive Heart FailureCardiovascularDec 2028
NCT06061549AAV1/SERCA2aPhase 1Heart Failure, DiastolicCardiovascularAug 2029

Targets

ATP2A2 (2)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.